Show simple item record

dc.contributor.authorToor, S
dc.contributor.authorElkord, Eyad
dc.date.accessioned2018-05-06T08:13:40Z
dc.date.available2018-05-06T08:13:40Z
dc.date.issued2018-04-10
dc.identifier.citationTherapeutic prospects of targeting myeloid-derived suppressor cells and immune checkpoints in cancer. 2018, Immunol Cell Biolen
dc.identifier.issn1440-1711
dc.identifier.pmid29635843
dc.identifier.doi10.1111/imcb.12054
dc.identifier.urihttp://hdl.handle.net/10541/620991
dc.description.abstractImmune evasion is a characteristic of most human malignancies and is induced via various mechanisms. Immunosuppressive cells, including myeloid-derived suppressor cells (MDSC) and regulatory T cells (Treg), are key mediators in assisting tumors to escape immune surveillance. Expansion of MDSC, Treg and elevated levels of immune checkpoints (IC) are frequently detected in the tumor microenvironment and periphery of cancer patients. Various therapeutic agents have been shown to target MDSC and to block IC for inducing anti-tumor immunity and reversal of tumor immune escape. Importantly, some recent studies have shown that MDSC targeting improves the efficacy of IC blockade in cancer therapy. However, there is a pressing need to improve our understanding of the distinct role of these cells to develop combination therapy that attacks tumor cells from all frontiers to improve cancer therapeutics. Herein, we discuss the role of MDSC in cancer progression, interactions with IC in the context of anti-cancer immunity and the current therapeutic strategies to target MDSC and block IC in cancer.
dc.language.isoenen
dc.rightsArchived with thanks to Immunology and cell biologyen
dc.titleTherapeutic prospects of targeting myeloid-derived suppressor cells and immune checkpoints in cancer.en
dc.typeArticleen
dc.contributor.departmentImmunol Cell Biolen
dc.identifier.journalImmunology and Cell Biologyen
html.description.abstractImmune evasion is a characteristic of most human malignancies and is induced via various mechanisms. Immunosuppressive cells, including myeloid-derived suppressor cells (MDSC) and regulatory T cells (Treg), are key mediators in assisting tumors to escape immune surveillance. Expansion of MDSC, Treg and elevated levels of immune checkpoints (IC) are frequently detected in the tumor microenvironment and periphery of cancer patients. Various therapeutic agents have been shown to target MDSC and to block IC for inducing anti-tumor immunity and reversal of tumor immune escape. Importantly, some recent studies have shown that MDSC targeting improves the efficacy of IC blockade in cancer therapy. However, there is a pressing need to improve our understanding of the distinct role of these cells to develop combination therapy that attacks tumor cells from all frontiers to improve cancer therapeutics. Herein, we discuss the role of MDSC in cancer progression, interactions with IC in the context of anti-cancer immunity and the current therapeutic strategies to target MDSC and block IC in cancer.


This item appears in the following Collection(s)

Show simple item record